Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin.
about
Fusion toxin BLyS-gelonin inhibits growth of malignant human B cell lines in vitro and in vivoGenetic reprogramming of tumor cells by zinc finger transcription factorsUbiquitous mitochondrial creatine kinase downregulated in oral squamous cell carcinoma.Phase I trial of systemic intravenous infusion of interleukin-13-Pseudomonas exotoxin in patients with metastatic adrenocortical carcinoma.Intracellular trafficking considerations in the development of natural ligand-drug molecular conjugates for cancer.Clinical development of experimental therapies for malignant glioma.Histone modification enhances the effectiveness of IL-13 receptor targeted immunotoxin in murine models of human pancreatic cancer.Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation.Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinomaTargeting of interleukin-13 receptor α2 for treatment of head and neck squamous cell carcinoma induced by conditional deletion of TGF-β and PTEN signaling.Overexpression of interleukin-13 receptor-alpha2 in neuroendocrine malignant pheochromocytoma: a novel target for receptor directed anti-cancer therapy.Specific targeting of human interleukin (IL)-13 receptor α2-positive cells with lentiviral vectors displaying IL-13.Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model.Targeted toxins in brain tumor therapy.Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity.
P2860
Q27314650-0B6DABA2-C748-4D32-AD46-9B0FC709A34CQ33221141-96C77F08-8320-490F-A855-AAE0A66842D4Q33233938-2E654FEF-234D-4F31-BD3A-DB0ACED9CB82Q33421178-FF5236C8-F7EC-44D9-91C2-917A44D12D9FQ34751465-3CEC85FC-D15A-46D3-83AF-37BE5E4A9440Q34782295-204FE7D0-D744-428B-9492-00D1261376D5Q34988874-B08A2B1C-091C-4FD5-A76D-83FC633152B8Q35584244-34B840DE-0759-4C39-B919-46D051D0558AQ36157337-B5707AFE-68D3-4F79-937A-76BBD1C03E2EQ36686360-72C440AF-2254-4671-A469-A5AEB05AE155Q37315697-1F5ADB3B-CA0B-45B6-A525-9035695CE9A2Q37358531-492D66AF-EBEC-4C64-AB26-072AC1F344E7Q37372980-4DFC43A7-45D8-4726-B44A-861FA976C7B8Q37954275-05C759A9-7BAF-4D3C-9AB8-52087FFCD66EQ42133458-C1446067-FE48-4080-B88C-3E5773EE68C7
P2860
Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Heterogeneity in interleukin-1 ...... form of Pseudomonas exotoxin.
@en
type
label
Heterogeneity in interleukin-1 ...... form of Pseudomonas exotoxin.
@en
prefLabel
Heterogeneity in interleukin-1 ...... form of Pseudomonas exotoxin.
@en
P2093
P1476
Heterogeneity in interleukin-1 ...... d form of Pseudomonas exotoxin
@en
P2093
Bharat H Joshi
Koji Kawakami
Pamela Leland
Raj K Puri
P304
P407
P577
2002-06-01T00:00:00Z